SCHEMBL925027

SCHEMBL925027

CC(=O)Nc1nc(C)c(-c2ccc(Cl)nc2)s1

nearest known ligand 0.64

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 19/20 0.64
PIK3CD O00329 13/20 0.64
PIK3CA P42336 12/20 0.64
PIK3CB P42338 12/20 0.64
PIK3C3 Q8NEB9 3/20 0.52
PIK3C2A O00443 1/20 0.52
PIK3C2B O00750 1/20 0.52
PI4KA P42356 1/20 0.52
PRKDC P78527 1/20 0.52
PI4KB Q9UBF8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL924501 0.92 PIK3CG (0.55) PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3
SCHEMBL924622 0.84 PIK3CG (0.64) PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3
SCHEMBL4201829 0.82 PIK3CG (0.61) PIK3CGPIK3CDPIK3CAPIK3CBPIK3C2A
SCHEMBL923907 0.82 PIK3CG (0.63) PIK3CGPIK3CDPIK3CAPIK3CBPI4KB
SCHEMBL13948300 0.81 PIK3CG (0.70) PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3
SCHEMBL4209112 0.81 PIK3CG (0.62) PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3
SCHEMBL924512 0.81 PIK3CG (0.61) PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3
SCHEMBL924832 0.80 PIK3CG (0.60) PIK3CGPIK3CDPIK3CAPIK3CBPI4KB
SCHEMBL48461 0.79 PIK3CG (0.76) PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3
SCHEMBL4197749 0.79 PIK3CG (0.53) PIK3CGPIK3CDPIK3CAPIK3CBPIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344153-B2 Inhibitors of phosphatidylinositol 3-kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-01 US disclosed
US-7868188-B2 5-heteroaryl thiazoles and their use as PI3K inhibitors ASTRAZENECA AB (SE) 2011-01-11 US disclosed
US-20100316605-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-16 US disclosed
WO-2010144513-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-12-16 WO disclosed
US-20080132502-A1 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors ASTRAZENECA AB (SE) 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316605-A1 INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CA, PIK3CG, PIK3CD PIK3CG 2/4885PIK3CD 3/4885PIK3CA 1/4885
US-20080132502-A1 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors MTOR, PIK3R5, PIK3CA PIK3CG 16/4885PIK3CD 6/4885PIK3CA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.